Figure 5 | Scientific Reports

Figure 5

From: siRNA capsulated brain-targeted nanoparticles specifically knock down OATP2B1 in mice: a mechanism for acute morphine tolerance suppression

Figure 5

Investigate the character and stability of DGL-PEG/dermophin/siRNA (OATP2B1) NPs in vitro and in vivo.

(A) The stability test for NPs was performed by formaldehyde modified gel electrophoresis with different weight ratios of 0.5:1, 1:1, 2:1, 4:1, 6:1, 10:1, 15:1, 20:1 for DGL-PEG/dermorphin to siRNA (OATP2B1); (B) The functions estimation of NPs were detected by immunofluorescence assay in bEnd.3 cells. Intensity of red fluorescence signal was revealing the target expression level; (C) mRNA expression of OATP2B1 was measured in bENd.3 cells after siRNA (OATP2B1) capsulated NPs transfected for 48 h, DGL-PEG/dermorphin and blank bEnd.3 cells are being as negative control. (D) DGL-PEG/dermorphin/siRNA (OATP2B1) NPs or siRNA transfected in nude mice for 1 h after anesthesia observed by in vivo imaging. (E) The X-ray imaging of nude mice reflected the actual tissues position. Pairwise comparisons were calculated by student t-test to calculate P values (*P < 0.05) in qPCR assay (n = 3).

Back to article page